Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises

Aristotle Capital Management's Core Equity Fund sold its position in Boston Scientific Corporation (BSX) due to concerns about slowing growth in its key medical device franchises, Watchman and Farapulse. Despite positive clinical trial data, Watchman's growth is declining due to implantation modality changes and market hesitation, while Farapulse faces increased competition. The fund believes it will take time for Boston Scientific to regain investor confidence and its premium valuation.